Pathogenesis, prevention, diagnosis and treatment of breast cancer.
暂无分享,去创建一个
[1] Bernard Rachet,et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). , 2008, The Lancet. Oncology.
[2] J. Bryant,et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Brinton,et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia , 1993, Cancer.
[4] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.
[5] S Shapiro,et al. Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. , 1985, National Cancer Institute monograph.
[6] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[7] Eero Pukkala,et al. Breast cancer in Belarus and Ukraine after the Chernobyl accident , 2006, International journal of cancer.
[8] E. Conant,et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management , 2001, Cancer.
[9] G. Colditz,et al. Family history and risk of breast cancer: nurses’ health study , 2012, Breast Cancer Research and Treatment.
[10] Jean B. Cormack,et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. , 2008, JAMA.
[11] T. McCready,et al. Breast self-examination and breast awareness: a literature review. , 2005, Journal of clinical nursing.
[12] Thea D. Tlsty,et al. Benign breast disease and the risk of breast cancer. , 2005 .
[13] Marc Buyse,et al. Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.
[14] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[15] H. D. de Koning,et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.
[16] D. L. Preston,et al. Solid Cancer Incidence in Atomic Bomb Survivors: 1958–1998 , 2007, Radiation research.
[17] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[18] Dongfeng Zhang,et al. Physical activity and risk of breast cancer: a meta-analysis of prospective studies , 2013, Breast Cancer Research and Treatment.
[19] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[20] P. Gøtzsche,et al. Regular self-examination or clinical examination for early detection of breast cancer. , 2003, The Cochrane database of systematic reviews.
[21] R. Carlson. NCCN breast cancer clinical practice guidelines in oncology: an update. , 2003, Journal of the National Comprehensive Cancer Network : JNCCN.
[22] Lihong Qi,et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. , 2013, Journal of the National Cancer Institute.
[23] J. Ranstam,et al. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease , 2002, The Lancet.
[24] J L Kelsey,et al. Reproductive factors and breast cancer. , 1993, Epidemiologic reviews.
[25] N. Risch,et al. Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994 .
[26] K Vajda,et al. [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.
[27] B. E. F. Isher,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .
[28] Gerald Gartlehner,et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. , 2013, The Cochrane database of systematic reviews.
[29] M. Stampfer,et al. Insulin receptor expression and function in human breast cancer cell lines. , 1992, Cancer research.
[30] F. Berrino,et al. Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort , 2009, Cancer Epidemiology Biomarkers & Prevention.
[31] A. Luini,et al. Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study , 2010, Annals of surgery.
[32] Umberto Veronesi,et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.
[33] S. Paik,et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Stephen W Duffy,et al. A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.
[35] R. Collins,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[36] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[37] Christi J. van Asperen,et al. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? , 2009, Breast Cancer Research and Treatment.
[38] V Shane Pankratz,et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Thomas E Rohan,et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. , 2009, Journal of the National Cancer Institute.
[40] S. Edge,et al. Prognostic factors in breast cancer , 2005 .
[41] Leif E. Peterson,et al. Validity of Models for Predicting BRCA1 and BRCA2 Mutations , 2007, Annals of Internal Medicine.
[42] Giovanni Parmigiani,et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] S. Shapiro,et al. Evidence on screening for breast cancer from a randomized trial , 1977, Cancer.
[44] D. Dershaw,et al. Detection of local recurrence after conservative therapy for breast carcinoma , 1992, Cancer.
[45] S. Yuasa,et al. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: Associations and interactions in an international case‐control study , 1990, International journal of cancer.
[46] W. Willett,et al. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. , 2011, JAMA.
[47] Nazneen Rahman,et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.
[48] M. King,et al. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.
[49] D. Vanel. The American College of Radiology (ACR) Breast Imaging and Reporting Data System (BI-RADS): a step towards a universal radiological language? , 2007, European journal of radiology.
[50] Edward Azavedo,et al. Guidelines for International Breast Health and Cancer Control – Implementation Supplement to Cancer Guideline Implementation for Breast Healthcare in Low-Income and Middle-Income Countries Overview of the Breast Health Global Initiative Global Summit 2007 , 2008 .
[51] D. Evans,et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening , 2007, Journal of Medical Genetics.
[52] Lesley McGuffog,et al. Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.
[53] T. Nielsen,et al. Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] J. Kievit,et al. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] L. Carey,et al. Impact of Breast Cancer Molecular Subtypes on Locoregional Recurrence in Patients Treated with Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer , 2011, Annals of Surgical Oncology.
[56] J Benichou,et al. Graphs to estimate an individualized risk of breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] H. Nelson,et al. Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.
[58] P. Gøtzsche,et al. Screening for breast cancer with mammography. , 2013, The Cochrane database of systematic reviews.
[59] G. Hortobagyi,et al. Current status of adjuvant systemic therapy for primary breast cancer: Progress and controversy , 1995, CA: a cancer journal for clinicians.
[60] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.
[61] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] S. Paik,et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] A E Giuliano,et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] R Peto,et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.
[65] B. Mukesh,et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[67] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[68] R. Goldbohm,et al. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.
[69] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[70] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[71] Julian Peto,et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.
[72] H. Lynch,et al. Breast cancer genetics in an oncology clinic: 328 consecutive patients. , 1986, Cancer genetics and cytogenetics.
[73] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[74] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[75] K. Kelly,et al. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts , 2009, European Radiology.
[76] A Howell,et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.
[77] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[78] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[79] G. Colditz,et al. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.
[80] G. Bonadonna,et al. Patterns of Relapse and Survival in Operable Breast Carcinoma with Positive and Negative Axillary Nodes , 1978, Tumori.
[81] Gordon B Mills,et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. , 2002, Journal of the National Cancer Institute.
[82] Scott Davis,et al. Implementation of the Women's Health Initiative study design. , 2003, Annals of epidemiology.
[83] Jong-Hyeon Jeong,et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. , 2002, The New England journal of medicine.
[84] D Spiegelman,et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.
[85] Karla Kerlikowske,et al. Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer , 2010, Breast Cancer Research and Treatment.
[86] D. Hicks,et al. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. , 2008, American journal of clinical pathology.
[87] M. Mathieu,et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] A. Giuliano,et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.
[89] R. Gelber,et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.
[90] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[91] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[92] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[93] D. Plewes,et al. Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer , 2008, Annals of Internal Medicine.
[94] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[95] D. Evans,et al. Familial Breast Cancer , 2012, Clinical genetics.
[96] D. Smetherman,et al. Screening, imaging, and image-guided biopsy techniques for breast cancer. , 2013, The Surgical clinics of North America.
[97] C. Criscitiello,et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[99] P. Ravdin,et al. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.
[100] I. Gram,et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study , 2012, Breast Cancer Research.
[101] S. Nathanson,et al. Multidisciplinary breast cancer clinics , 1997 .
[102] Les Irwig,et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. , 2010, European journal of cancer.
[103] F. Clavel-Chapelon,et al. Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC) , 2004, International journal of cancer.
[104] D. Freedman,et al. On the efficacy of screening for breast cancer. , 2004, International journal of epidemiology.
[105] B Rosner,et al. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. , 1994, American journal of epidemiology.
[106] Melissa M. Hudson,et al. Systematic Review: Surveillance for Breast Cancer in Women Treated With Chest Radiation for Childhood, Adolescent, or Young Adult Cancer , 2010, Annals of Internal Medicine.
[107] A. Lindblom,et al. Family History, and Impact on Clinical Presentation and Prognosis, in a Population-based Breast Cancer Cohort from the Stockholm County , 2006, Familial Cancer.
[108] Majid Ezzati,et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors , 2005, The Lancet.
[109] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[110] R. Scott,et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer , 2011, Breast Cancer Research and Treatment.
[111] S. Shapiro,et al. Periodic breast cancer screening in reducing mortality from breast cancer. , 1971, JAMA.
[112] Ingvar Andersson,et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials , 2002, The Lancet.